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Abstract
Administration of the thienopyridine P2Y12 receptor antagonist, clopidogrel, increased the erosive arthritis induced by
peptidoglycan polysaccharide (PG-PS) in rats or by injection of the arthritogenic K/BxN serum in mice. To determine if the
detrimental effects are caused exclusively by clopidogrel, we evaluated prasugrel, a third-generation thienopyridine pro-
drug, that contrary to clopidogrel is mostly metabolized into its active metabolite in the intestine. Prasugrel effects were
examined on the PG-PS-induced arthritis rat model. Erosive arthritis was induced in Lewis rats followed by treatment with
prasugrel for 21 days. Prasugrel treated arthritic animals showed a significant increase in the inflammatory response,
compared with untreated arthritic rats, in terms of augmented macroscopic joint diameter associated with significant signs
of inflammation, histomorphometric measurements of the hind joints and elevated platelet number. Moreover, fibrosis at
the pannus, assessed by immunofluorescence of connective tissue growth factor, was increased in arthritic rats treated with
prasugrel. In addition to the arthritic manifestations, hepatomegaly, liver granulomas and giant cell formation were
observed after PG-PS induction and even more after prasugrel exposure. Cytokine plasma levels of IL-1 beta, IL-6, MIP1
alpha, MCP1, IL-17 and RANTES were increased in arthritis-induced animals. IL-10 plasma levels were significantly decreased
in animals treated with prasugrel. Overall, prasugrel enhances inflammation in joints and liver of this animal model. Since
prasugrel metabolites inhibit neutrophil function ex-vivo and the effects of both clopidogrel and prasugrel metabolites on
platelets are identical, we conclude that the thienopyridines metabolites might exert non-platelet effects on other immune
cells to aggravate inflammation.
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Introduction
For decades, decreasing platelet activation has been a target in
the prevention of coronary artery disease [1] and an array of drugs
have been discovered to selectively interfere with platelet function.
Among those are prasugrel and clopidogrel, thienopyridine
compounds that antagonized the P2Y12 receptor in platelets.
Prasugrel was approved by the Food and Drug Administration of
the United States to be used to reduce risk of thrombus formation
on patients undergoing for percutaneous coronary intervention.
However, prasugrel, a pro-drug that is considered more potent
than clopidogrel, has been associated with an increased risk of
primarily gastrointestinal bleeding [1]. Unlike other thienopyr-
idine drugs, prasugrel is more easily metabolized than clopidogrel
into its active and inactive metabolites, requiring fewer steps in the
liver. The active metabolite binds covalently and irreversibly to the
P2Y12 receptor [2,3] and inhibits platelets more rapidly, potently
and consistently than clopidogrel. Recently, clopidogrel response
variability and drug resistance among patients has been reported
due to the loss-of-function allele CYP2C19*2 [4]. In contrast,
prasugrel treatment has not being implicated with any polymor-
phism and has shown higher efficacy than high-dose clopidogrel
[5].
Increasing reports of development of arthritis, in particular
acute migratory polyarthritis after clopidogrel regimen, raise the
need for alternative treatments [6–13]. Prasugrel has not being
implicated in these arthritogenic events, although prasugrel is a
recent drug that has narrower clinical indications than clopidogrel.
Koshal and co-workers [9] proposed prasugrel as an alternative
anti-thrombotic drug to reduce the risk of drug-induced-arthritis.
Platelets and platelet micro particles have been implicated in the
perpetuation of arthritis, as shown by Lee and co-workers [14],
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who demonstrated aggravation of arthritis in the presence of micro
particles from platelets. In their murine model, they demonstrated
that the administration of serum from K/BxN animals provoked
erosive arthritis in C57BL/6J mice and the daily administration of
clopidogrel resulted in increased joint diameter and inflammation
[14]. Comparable results were observed in a rat model of erosive
arthritis induced by peptidoglycan polysaccharide PG-PS after
treatment with clopidogrel [15], which raise concerns of the use of
clopidogrel in patients with rheumatoid arthritis (RA). The
ultimate mechanism of the detrimental effect of clopidogrel
treatment observed in these two animal models is still unknown.
Therefore, this study is intended to evaluate prasugrel, a
thienopyridine pro-drug, in inflammation and to further investi-
gate how these drugs affect inflammatory processes.
Materials and Methods
Erosive Arthritis Induction and Assessment
Thirty-two female pathogen-free Lewis rats obtained from
Charles River Laboratories (Raleigh, NC), weighing between 160 -
180 grams, were randomly separated into the experimental groups
and studied for 21 days. Sixteen animals received a single dose of
15 mg of rhamnose/gram of mean body weight of purified, sterile,
PG-PS polymer (BD Lee Laboratories, Grayson, GA), adminis-
tered by intraperitoneal (i.p.) injection on day 0. Of those animals,
8 animals, the PG-PS+prasugrel group, received 3 mg/kg daily
oral dose of prasugrel (EffientH 10 mg tablets, prasugrel hydro-
chloride dissolved in 0.5% carboxyl methylcellulose as vehicle
solution (Sigma-Aldrich Chemicals, St. Louis, MO), and the other
8, the PG-PS group, received only the vehicle solution. The other
16 animals received no PG-PS, 8 received oral daily dose of
prasugrel and 8 received oral daily vehicle solution. Animals were
weighed and examined daily. Under anaesthesia (EZ 1500,
anaesthesia System from Euthanex Corp., for isofluorane [VetOne
Pharmaceuticals]), ankle diameter was measured and arthritis
severity was assessed as previously described [15,16]. At day 21,
rats were anesthetized, and blood samples were collected by
cardiac puncture for hematology, plasma separation and for serum
collection for chemical analyses. A 10:1 ratio of blood in 3.8%
sodium citrate was used as anticoagulant. The experimental
protocol used in this study was fully approved by The Institutional
Animal Care and Use Committee of Temple University School of
Medicine.
Figure 1. Prasugrel increases the clinical and pathological manifestations of PG-PS-induced arthritis. (A) Daily measurements of ankle
joint diameter. Values represent the change of hind paw diameter in millimetres (n = 16 measurements [8 rats] per group). Values plotted are the
mean 6 SEM of the measurements. *p,0.05 and ***p,0.001 between PG-PS+prasugrel vs. PG-PS groups. (B) Macroscopic images of paw and ankle
joint of the animals at day 21. Increase joint diameter associated with visible signs of inflammation.
doi:10.1371/journal.pone.0069093.g001
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Figure 2. Differences observed in the PG-PS-induced erosive arthritis after prasugrel treatment. Histological examination of ankle joints
of rats from different groups of sections stained with H&E at 2X and 106magnifications (A and B, respectively). Sections from untreated animals (not
shown) and prasugrel alone revealed no histopathological signs of inflammation. (C) CTGF expression was assessed with fluorescence microscopy
(green – FITC). Images are representative of 4 different animals per group. Lower and right photographs underneath are representative of the control
isotype stainings. (D) Histopathological score. Values plotted are the mean of the measurements 6 SEM, (n = 4 per group) **p,0.01. b, bone; ss,
synovial space; p, pannus.
doi:10.1371/journal.pone.0069093.g002
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Hematology, Platelet and Blood Chemistry Studies
Fifty microliters of anticoagulated blood was used to carry out a
detailed hematologic profile from each animal, utilizing the
HemavetH Multispecies Hematology System (Drew Scientific,
Inc. Oxford, CT). Then, total blood was centrifuged in
polypropylene tubes at 22uC at 1006g for 10 min to obtain
platelet rich plasma (PRP). PRP was centrifuged again at 4006g
for 10 min. Platelet-poor plasma was recovered and aliquots of
supernatant were stored at 270uC for cytokine profile studies.
Platelet pellets after centrifugation were resuspended in Tyrodes
buffer (pH 7.4) containing 0.05 units/mL apyrase. Platelets were
counted using the HemavetH System. Aggregation was measured
using light transmission under stirring conditions (900 rpm) at
37uC (P.I.C.A. Lumiaggregometer [Chrono-log Corp., Haver-
town, PA]). Aggregation tracings of 0.5 mL of washed platelets
from each animal were recorded.
Serum from each animal was analyzed for chemistry profile
including cholesterol, triglycerides, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phosphatase,
total bilirubin, glucose, phosphate, total protein, blood urea
nitrogen (BUN), creatinine, albumin, calcium, sodium, potassium,
and chloride levels (Charles River Laboratories, MA).
Histopathology and Immunofluorescence
Hind paws were prepared as previously described [15–17]. In
brief, samples were fixed, decalcified, embedded in paraffin,
sectioned and stained with hematoxylin and eosin for microscopy.
The degree of inflammation and articular injury was measured by
a score system previously described in detail [15,18–20].
Pathologic parameters were measured for synovial hyperplasia,
cell infiltration, neovascular formation, fibrosis and pannus
formation. The histopathological score ranged from 0 to 24.
Since in addition to joint inflammation, i.p. PG-PS-injection
develops hepatomegaly and granuloma formation, liver was
weighed and the percentage of the organ from the total body
weight was calculated and plotted. Liver granuloma formation was
assessed and measured using BioquantH software as previously
described [16]. In brief, a percentage of the granuloma area over
the total tissue area was calculated by tracing the perimeter of each
granuloma. Several histological sections of the different groups
were analyzed and plotted.
To further evaluate fibrosis in the affected joint tissue, we
measured connective tissue growth factor (CTGF) protein levels by
immunofluorescence, using previously described methods [16]. In
brief, slides from the rat groups were deparaffinized, rehydrated
and blocked with 10% BSA in HBSS buffer solution, followed by
overnight incubation with monoclonal CTGF antibody (sc-
101586, Santacruz Biotechnology Inc, CA). Slides were washed
and then incubated with anti-mouse IgG-FITC labelled (sc-2010,
Santacruz Biotechnology Inc, CA) for microscopy analysis.
Control staining slides incubated with anti-mouse IgG conjugated
isotype were used to evaluate non-specific binding. Immunofluo-
rescence present in the tissue was quantified as a percentage of the
area of CTGF immunoreactivity by Image J software.
Plasma Cytokine Profiles
Plasma aliquots from each animal were utilized for detection of
interleukin (IL)-1b, IL-4, IL-6, IL-10, IL-17, macrophage inflam-
matory protein (MIP)-1a; monocyte chemotactic protein (MCP)-1,
tumor necrosis factor (TNF)-a and regulated upon activation,
Figure 3. Increase in liver granuloma formation in the prasugrel treated PG-PS-induced animals. Photographs of liver tissue, stained
with H&E, showing the formation of granulomas in the hepatic tissue. Upper panel photographs represent hepatic tissue at 26magnification (A) and
middle panel photographs are magnifications of granulomas (10X) (B) with the presence of giant cells (40X) (C). Images are representative of 4
animals per group. Percentage of granuloma area in the liver (**p,0.01) (D) and the presence of giant cells at the granuloma (*p,0.05) (E) were
measured and plotted. Values represent the mean 6 SEM, (n = 6).
doi:10.1371/journal.pone.0069093.g003
Figure 4. Hematology cell counts following prasugrel treat-
ment in PG-PS- induced arthritis model. White blood cells (WBC)
(A), differential (B) and platelet (C) blood counts at day 21. Cell counts
are 103/mL. Values are mean 6 SEM, (n = 6), **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0069093.g004
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normally t-expressed and presumably secreted chemokine
(RANTES) plasma levels by the LuminexH System (AssayGate,
Inc. Ijamsville, MD). Plasma levels of platelet factor 4 (PF4) were
measured by ELISA (AssayGate, Inc. Ijamsville, MD).
Statistical Analysis
Differences among groups were statistically analyzed using one-
way analysis of variances (ANOVA); Bonferroni’s multiple
comparison test was used as post-test analyses. P,0.05 was
considered to be significant. The joint diameter was analyzed as a
continuous variable of all analyses. Hepatic granuloma area and
giant cell number was analyzed by two-way unpaired t-test. Data
are reported as mean 6 standard error of the mean (SEM) for
each group.
Results
PG-PS-induced Arthritis Animals Treated with Prasugrel
Exhibit Greater Clinical Signs of Arthritis
To evaluate the effect of prasugrel during inflammation, PG-PS
was administered to rats at the beginning of the study. Daily paw
diameter was measured to evaluate and document the progression
of the erosive arthritis. The paw diameter in the PG-PS arthritis-
induced animals was significantly increased after the PG-PS
injection following the typical biphasic pattern, acute and chronic
phases, observed in this animal model (panel A of Fig. 1). From
those animals, the addition of prasugrel showed greater increase in
paw diameter during the acute phase (days 4 to 6, *p,0.05).
Further increase in paw diameter was observed during the chronic
phase with prasugrel treatment (days 13 to 21, ***p,0.001). It is
important to mention that all PG-PS-induced arthritis animals
reached a plateau in the diameter measurements at the beginning
of the chronic phase. However, the joints of the prasugrel-treated
animals were notably more inflamed and with visible signs of
severe arthritis than the joints of the PG-PS animals (panel B of
Fig. 1). Since we found no differences in any of the parameters
evaluated between the untreated group and prasugrel alone group,
hereafter we will refer those groups as control groups, unless
specified otherwise.
Histomorphometric and Immunofluoresce Analyses of
the Limb Joints Confirmed the Macroscopic Findings
Histology of the ankle joints of the prasugrel-treated animals
revealed greater synoviocyte hyperplasia, leukocyte infiltration,
fibrosis, bone destruction, and pannus formation than the joints of
the PG-PS controls (panel A of Fig. 2). Photographs were taken
from the histology slides at 26magnification to show the tibio-
tarsal articulation. In the joints of the control groups (untreated
[not shown] and prasugrel alone groups), the synovial space
remained intact and limited by the synovium of single lining of
cells and intact bone surface. In contrast, joints of the PG-PS-
induced arthritis animals showed signs of chronic inflammation:
the synovium was covered with multiple layers of cells, the synovial
space was invaded with pannus, the peri-synovial tissues were
infiltrated with inflammatory cells, normal tissue became fibrotic
and the bone was severely eroded and deformed. Greater detail is
appreciated at 106magnification of the tibio-tarsal joint (panel B
of Fig. 2), where the severe synovial hyperplasia and the
neovascular formation can be observed. Overall, in all the
Figure 5. Platelet aggregation studies using 2MeSADP. Effect of 2MeSADP (100 nM) on platelet aggregation in washed platelets isolated from
the blood of the rats. Traces are representative (n = 3) of each of the groups of the study.
doi:10.1371/journal.pone.0069093.g005
Table 1. Cytokine profile.
Cytokine Untreated Prasugrel PG-PS
PG-
PS+Prasugrel
IL-1b 44.66611.64 30.65612.86 88.6623.19 104.1616.39*
IL-6 21.4262.71 21.9661.99 142.0627.59** 119.4615.11*
IL-4 21.8162.82 14.6863.91 11.7461.62 11.0561.34
IL-10 412.46268.2 391.26118.9 539.86221.5 17.8161.91**,{{
IL-17 0.9960.08 0.9460.09 685.96301.5** 246.8650.18*
PF4 1.6060.22 1.0960.56 1.760.38 2.2960.90**
MCP-1 89.7264.87 83.4762.79 398.0679.21** 447.7669.06**
TNF a 17.0861.87 13.0660.55 15.2461.03 13.1160.55
RANTES 12.0862.13 12.1762.74 24.5464.12 28.9762.77
MIP1 a 4.5860.2 5.0860.68 10.6862.47 10.961.4*
Plasma cytokine levels in rats following prasugrel administration in PG-PS
induced arthritis model.
All values are in pg/mL except for RANTES that are in ng/mL. Values represent
the mean 6 SEM.
*p,0.05,
**p,0.01 (vs. control groups [untreated group and prasugrel group]).
{{p,0.01 (vs. PG-PS group).
doi:10.1371/journal.pone.0069093.t001
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histology parameters evaluated, the severity of the arthritis was
greater in the prasugrel treated animals.
The downstream protein of the transforming growth factor beta
(TGF-ß) pathway, CTGF, is considered an excellent marker for
fibrosis in cartilage and bone tissue. Tissue fibrosis assessed by
immunofluoresce of CTGF was increased in arthritic rats treated
with prasugrel. CTGF protein expression was significantly
increased in the prasugrel treated arthritic animals compared to
prasugrel alone control. Immunofluorescence levels of CTGF in
the PG-PS control were 4.0860.17 (% area CTGF immunore-
activity) and the PG-PS+prasugrel group values were 9.0560.22
(% area CTGF immunoreactivity), ***p,0.001. Representative
photographs of the immunofluorescence are shown in panel C of
Fig. 2. Underneath of each photograph in panel C are
representative small pictures of the isotype control stainings.
Measurements of the pathological changes in the joints were
assessed and quantified as previously described [15]. The
synoviocyte hyperplasia, measured as the predominant cell depth
of the synovial lining, was 1361.72 SEM in PG-PS control
animals vs. 50.1465.46 SEM in prasugrel treated animals.
Proliferative blood vessels quantified as the number of vessels
per high power field (HPF) was 7.560.34 SEM in PG-PS control
animals vs. 17.8363.75 SEM in prasugrel treated animals. The
percentage of perivascular infiltrates of leukocytes was 50.89%
62.6 SEM in PG-PS control animals vs. 92.2962.82 SEM in
prasugrel treated animals. The percentage of fibrotic tissue was
20.9962.86 SEM in PG-PS control animals vs. 44.5762.44 SEM
in prasugrel treated animals. All of these parameters were
summarized in the histopathological score, which as
10.6761.66 SEM for PG-PS control animals while in the PG-
PS+prasugrel treated animals was 19.561.18 SEM (**p,0.01)
(Panel D of Fig. 2). These results are in accordance with the
physical manifestations observed in the animals.
Hepatomegaly with Granuloma Formation was
Associated with PG-PS Induction and Increased with
Prasugrel Treatment
Besides the arthritic manifestations, we evaluated the inflam-
matory effects of PG-PS and the addition of prasugrel treatment in
liver. All animals treated with PG-PS showed an increase in organ
weight of the liver (2-fold increase from control groups).
Interestingly, not only was the liver granuloma area significantly
increased in animals treated with prasugrel (3-fold increase in
animals treated with prasugrel) (panels A, B and D of Fig. 3) but
more specifically, the numbers of giant cells were also increased in
prasugrel treated animals (2-fold increase in animals treated with
prasugrel) (panels C and E of Fig. 3). Indeed the effect of prasugrel
seems to aggravate liver pathology after PG-PS, and is not
localized to the joints. No difference was noted in liver histology
between healthy mice and prasugrel-treated healthy animals (data
not shown).
Neutrophil and Platelet Count are Increased in PG-PS-
induced Arthritis Animals Treated with Prasugrel
Compared to untreated rats, prasugrel treatment alone did not
alter the blood (Fig. 4, panels A–C). Both groups treated with PG-
PS showed an increase in WBC and platelet counts (Fig. 4. panels
A, C). The leukocytosis was driven primarily at the expense of the
number of neutrophils and secondarily to lymphocytes (Fig. 4,
panel B). Prasugrel treatment in arthritic animals resulted in
greater neutrophilia (PG-PS: 4.860.576103 cells/mL, PG-
PS+Prasugrel 10.466.66103 cells/mL, *p,0.05) (Fig. 4, panel B)
and thrombocytosis (PG-PS: 710.8652.656103 cells/mL vs. PG-
PS+Prasugrel 1,047689.036103 cells/mL, *p,0.05) (Fig. 4, panel
C). Notably, Prasugrel had not effect on lymphocyte count in
control or PG-PS treated rats. Platelet aggregation was inhibited
after treatment with prasugrel, in animals treated with prasugrel
alone and in animals treated with prasugrel and PG-PS-induced
arthritis (Fig. 5).
Proinflammatory Cytokines were Increased after PG-PS
Arthritis Induction and Plasma Levels of Interleukin 10
were Decreased in the PG-PS-induced Arthritis Animals
Treated with Prasugrel
The cytokine profile summarized in Table 1, showed an
increase in pro-inflammatory cytokines in both treated and
untreated PG-PS arthritis-induced animals, compared with control
animals. Interestingly, a trend of increase is shown for PF4, MCP-
1 and RANTES cytokines, confirming a greater increase in
inflammation levels when prasugrel was administrated. It is also
interesting to note that in the arthritis-induced animals treated
with prasugrel, the plasma levels of IL-10 were significantly
decreased. Note: treatment with prasugrel alone did not change
the cytokine profile.
Blood Chemistry Profile was not Altered with PG-PS-
induction
Serum levels of the blood chemistry profile showed no
differences among all groups (data not shown). Even though that
the majority of the active metabolite of prasugrel is produced in
the intestine, it is important to mention that no changes in hepatic
function after PG-PS induction suggest any impairment of the liver
to metabolize prasugrel.
Discussion
The high incidence of cardiovascular disease and the subse-
quent necessity for coronary intervention have led to a need for
safe and effective anti-thrombotic therapies. Among them,
clopidogrel has been used as the gold standard treatment to
reduce thrombus formation, and recently prasugrel has been
added as a therapeutic tool [21]. Previously we reported a
detrimental effect of clopidogrel administration in induced-
arthritis rats. This study aimed to evaluate the effect of prasugrel
in the same erosive arthritis model. Both clopidogrel and prasugrel
aggravated the arthritis manifestations and inflammation in these
rats, though there were several differences between both studies.
We observed that prasugrel aggravated the arthritis even in the
acute phase of the disease, as judged by a significant increment in
joint diameter of the animals, while clopidogrel did not [15].
Interestingly the ankle inflammation reached the highest grade of
severity by physical and/or histopathological parameters in some
animals treated with prasugrel. Even though we are aware of the
limitation of our comparisons between these two studies since they
were not performed side-by-side, these data suggest that prasugrel
compared with clopidogrel may affect the joints at different stages
of the disease and it may have an impact on the severity of the
arthritis.
Platelets and platelet-derived microparticles have been associ-
ated with inflammatory processes of autoimmune disorders
including rheumatoid arthritis, systemic lupus erythematosus and
sjo¨gren syndrome [14,22–27]. The study of the pathogenesis of
these platelet-derived microparticles has increased over the last
decade, and multiple mechanisms have been proposed
[14,23,24,27]. Platelet-derived microparticles have been directly
involved with leukocyte activation, monocytes in particular, during
Prasugrel Aggravates PG-PS-Induced Inflammation
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inflammation [28]. Prasugrel and clopidogrel are considered
selective antagonists of the P2Y12 receptor in platelets and inhibit
platelet microparticle generation [29]. Yet, studies treating animals
with thienopyridine compounds in the erosive arthritis model
suggest an effect of the active or inactive metabolites of the drug in
cells other than platelets, resulting in exacerbation of the
inflammatory response. Indeed Boillard et al [14] found an
increment in the diameter of the joints of the mice treated with
the arthritogenic K/BxN serum as well, however the purpose of
their study was to demonstrate the involvement of platelets in the
development of arthritis. To our knowledge, there is no
information related to inflammation levels and ankle joint
diameter after prasugrel treatment.
IL-10 plasma levels were dramatically decreased in the arthritic
prasugrel treated animals. The anti-inflammatory cytokine IL-10
is produced by monocytes and type II T helper cells [30,31] and
inhibits the cellular secretion of TNF-a, IL-1 and IL-6 [32]. Using
a murine animal model of arthritis, Kochetkova et al [33]
demonstrated a preventive effect against arthritis with overexpres-
sion of IL-4, IL-10 and TGF-b with subsequent reduction of IL-17
and IFN-c. Monocytes produce IL-10 upon activation by cell-to-
cell interaction or by response to other interleukins or factors.
Wang et al [34] reported mRNA expression of several P2Yrecep-
tors, including P2Y12, in monocytes and lymphocytes. The action
of the thienopyridine metabolites (active or inactive) may interact
with P2Y12 or other P2Y receptors present in monocytes or
lymphocytes, hence it may inhibit IL-10 synthesis with further
exacerbation of the immune response in this animal model.
Interestingly, these results are consistent with what previously
observed in arthritic animals treated with clopidogrel. In order to
evaluate the arthritogenic effect of activated platelets after
prasugrel treatment, we investigated plasma levels of PF4, which
is an anti-inflammatory chemokine released from the alpha
granules of activated platelets [35] and a potent chemo-attractant
for neutrophils, monocytes and fibroblasts [35]. In our previous
study using the PG-PS-induced erosive arthritis model when
clopidogrel administration aggravates arthritis, PF4 plasma levels
were elevated in PG-PS-induced animals, however there was no
difference with concomitant administration of clopidogrel [15]. In
this study, measurements of the PF4 levels showed an increased in
PF4 levels in all PG-PS-induced animals and even more with
prasugrel, suggesting a possible arthritogenic effect of activated
platelets after prasugrel treatment.
Visceral inflammatory manifestations of the PG-PS-induction
were studied as well. Formation of granulomas in liver was
observed in all animals induced by PG-PS after 21 days, however,
prasugrel treatments significantly increased liver inflammation.
Granuloma formation is mainly due to macrophage infiltration,
although other immune cells such as neutrophils and lymphocytes
play a role in the recruitment of monocytes into soft tissues. This
increased macrophage infiltration could be platelet-mediated;
therefore the decrease in platelet activity could alter the response
of other cells of the immune system. Alternatively, since both
monocytes and lymphocytes have shown to express P2Y12 receptor
[36], prasugrel active metabolites might directly target also these
cells, and alter monocyte differentiation into macrophages or
lymphocyte stimulation. Furthermore, other prasugrel metabolites
could interact with immune cells and alter their response to
inflammation. Our group have shown that neutrophil activation is
inhibited by prasugrel metabolites, despite the fact that these cells
did not seem to express P2Y12 receptor [37]. This inhibition of
neutrophil functions could be responsible for the increased levels of
inflammation observed after prasugrel exposure. To our knowl-
edge, the neutrophilia observed in this animal model after
prasugrel exposure has not being observed in humans treated
with any thienopyridine compound.
In summary, treatment with clopidogrel or prasugrel after
induction of arthritis by PG-PS resulted in aggravation of the
clinical manifestations of this animal model in the joints, but also
in liver damage probably due to increased cell activation. This
effect could be platelet-mediated, but as the effects of both
clopidogrel and prasugrel active metabolites on platelets are
identical, we conclude that the thienopyridines metabolites exert
off-target effects on other immune cells to cause aggravated
inflammation.
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